Cantor Fitzgerald Estimates ORIC FY2025 Earnings

ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) – Analysts at Cantor Fitzgerald issued their FY2025 earnings per share estimates for ORIC Pharmaceuticals in a report released on Tuesday, January 21st. Cantor Fitzgerald analyst P. Agrawal anticipates that the company will post earnings of ($2.32) per share for the year. Cantor Fitzgerald has a “Overweight” rating on the stock. The consensus estimate for ORIC Pharmaceuticals’ current full-year earnings is ($1.84) per share.

Other equities analysts have also recently issued research reports about the stock. HC Wainwright reaffirmed a “buy” rating and set a $21.00 price objective on shares of ORIC Pharmaceuticals in a research report on Monday, January 13th. Wedbush reissued an “outperform” rating and set a $20.00 target price on shares of ORIC Pharmaceuticals in a research note on Monday, January 13th. Finally, Wells Fargo & Company assumed coverage on ORIC Pharmaceuticals in a research note on Thursday, October 31st. They issued an “overweight” rating and a $20.00 price objective for the company. Eight investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock currently has an average rating of “Buy” and an average price target of $18.29.

ORIC Pharmaceuticals Stock Performance

NASDAQ:ORIC opened at $9.87 on Thursday. The stock’s fifty day moving average is $8.97 and its two-hundred day moving average is $9.54. ORIC Pharmaceuticals has a 52 week low of $6.33 and a 52 week high of $16.65.

ORIC Pharmaceuticals (NASDAQ:ORIC) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($0.49) EPS for the quarter, missing the consensus estimate of ($0.48) by ($0.01).

Institutional Trading of ORIC Pharmaceuticals

A number of large investors have recently made changes to their positions in ORIC. Creative Planning acquired a new position in ORIC Pharmaceuticals in the 3rd quarter valued at $116,000. Connor Clark & Lunn Investment Management Ltd. purchased a new stake in ORIC Pharmaceuticals in the third quarter valued at approximately $132,000. China Universal Asset Management Co. Ltd. increased its position in ORIC Pharmaceuticals by 71.3% during the third quarter. China Universal Asset Management Co. Ltd. now owns 13,568 shares of the company’s stock worth $139,000 after purchasing an additional 5,646 shares during the last quarter. XTX Topco Ltd purchased a new position in ORIC Pharmaceuticals during the second quarter worth approximately $153,000. Finally, Profund Advisors LLC grew its stake in shares of ORIC Pharmaceuticals by 23.6% during the 2nd quarter. Profund Advisors LLC now owns 21,861 shares of the company’s stock valued at $155,000 after buying an additional 4,175 shares during the period. Institutional investors and hedge funds own 95.05% of the company’s stock.

Insider Activity at ORIC Pharmaceuticals

In other news, CFO Dominic Piscitelli sold 8,851 shares of the stock in a transaction dated Monday, December 16th. The shares were sold at an average price of $8.28, for a total transaction of $73,286.28. Following the completion of the sale, the chief financial officer now owns 106,764 shares in the company, valued at approximately $884,005.92. This represents a 7.66 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Pratik S. Multani sold 8,850 shares of the stock in a transaction on Monday, December 16th. The stock was sold at an average price of $8.28, for a total value of $73,278.00. Following the sale, the insider now directly owns 46,765 shares of the company’s stock, valued at approximately $387,214.20. This represents a 15.91 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 42,361 shares of company stock valued at $350,749 over the last ninety days. Insiders own 5.55% of the company’s stock.

ORIC Pharmaceuticals Company Profile

ORIC Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, which is designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study; and ORIC-533, an orally bioavailable small molecule inhibitor of CD73, currently under Phase 1b study, being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens.